Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of leech polypeptide with antithrombotic and brain nerve cell protection and its application

A brain nerve cell, leech polypeptide technology, applied in extracellular fluid diseases, peptides, blood diseases, etc., can solve the problem of unclear active ingredients, and achieve the effect of improving neurobehavior, reducing brain edema, and being easy to prepare in large quantities.

Active Publication Date: 2020-11-13
JINAN UNIVERSITY
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported in the literature that leech extract has antithrombotic effects, regulates the expression of coagulation-related factors in endothelial cells (Chinese Journal of Arteriosclerosis, 2017, 25:1184-1188), and promotes the recovery of neurological function after cerebral ischemic injury [Journal of Nanchang University (Med. Edition), 2015,55:23-26], but did not specify its active ingredients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of leech polypeptide with antithrombotic and brain nerve cell protection and its application
  • A kind of leech polypeptide with antithrombotic and brain nerve cell protection and its application
  • A kind of leech polypeptide with antithrombotic and brain nerve cell protection and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1 Separation of polypeptide whitmantides A-C

[0056] (1) 3 kg of leeches were dried, washed, soaked, pulverized and homogenized with physiological saline, and the homogenate was freeze-thawed to obtain an extract. The obtained extract is processed by an ultrafiltration membrane with a molecular weight cut-off of 50KDa, and the ultrafiltrate part with a molecular weight of less than 50KDa is collected, and the obtained ultrafiltrate is subjected to solid-phase desalination, concentrated under reduced pressure or freeze-dried to obtain the total extract (13g) . Total extracts were separated by gel Sephadex G25 at 4-8°C. The ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS) method was used for analysis, tracking and detection, and the fractions containing the peptide compounds were collected, concentrated under reduced pressure or vacuum dried to obtain a peptide-enriched site (10 g).

[0057] (2) Take the polypeptide enriched part in step...

Embodiment 2

[0061] Example 2 Structural characterization of the polypeptide whitmantide A

[0062] The polypeptide whitmantide A prepared in Example 1 is an amorphous powder, UV (H 2 O)λ max (logε): 195(3.20). IR(KBr)ν max :3275.5,2960.2,1657.52,1541.81cm -1 . HR-ESI-MS m / z 658.4155[M+H] + (calcd for C 30 H 56 N 7 O 9 :658.4140). The N-terminal sequencing of whitmantide A was performed by Edman degradation method, and the amino acid sequence was determined to be NH 2 -Leu-Leu-Ser-Gly-Val-Leu-Gly-COOH. The MS / MS secondary mass spectrum showed that the a, b and y ion fragments of this compound were consistent with its amino acid sequence, and the above results further verified the amino acid linking sequence of whitmantide A. The results of Marfey analysis showed that whitmantide A contained two D-leucines and one L-leucine, and other chiral amino acids were all L-shaped. The absolute configuration of whitmantide A was determined by solid-phase synthesis. The positions of D- an...

Embodiment 3

[0063] Example 3 Structural characterization of the polypeptide whitmantide B

[0064] The polypeptide whitmantide B prepared in Example 1 is an amorphous powder, UV (H 2 O)λ max (logε): 196(3.18). IR(KBr)ν max :3275.5,2957.3,1640.16,1544.7,1132.97cm -1 ;HR-ESI-MS m / z715.4331[M+H] + (calcd for C 32 H 59 N 8 O 10 :715.4354). The N-terminal sequencing of whitmantide B was performed by Edman degradation method, and the amino acid sequence was determined to be NH 2 -Leu-Leu-Ser-Gly-Val-Leu-Gly-Gly-COOH. MS / MS secondary mass spectrum showed that the a, b and y ion fragments of this compound were consistent with its amino acid sequence, and the above results further verified the amino acid linking sequence of whitmantide B. The results of Marfey analysis showed that whitmantide B contained two D-leucines and one L-leucine, and other chiral amino acids were all L-type. The absolute configuration of whitmantide B was determined by solid-phase synthesis. The positions of D-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
recovery rateaaaaaaaaaa
Login to View More

Abstract

The invention discloses hirudo polypeptide with functions of antithrombus and brain nerve cell protection and application of the hirudo polypeptide, and relates to the fields of traditional Chinese medicine, natural medicine and health care products. The structure of the hirudo polypeptide is presented as a formula I, human umbilical vein endothelial cell expressing vascular hemophilia factor (vWF) and a plasminogen activator inhibitor-1(PAI-1) can be significantly lowered at the low concentration of the hirudo polypeptide, the survival rate of nerve cells after oxygen and glucose deprivationis increased, platelet aggregation in vitro is inhibited, the plasma recalcification time is prolonged, formation of thrombi in vivo is reduced, neurobehavior after cerebral infarction of a rat is improved, encephaledema is relieved, the area of cerebral infarction is reduced, the toxicity is low, good application prospects are achieved, and the hirudo polypeptide can be used for preparing medicine or health care products for treating or adjuvant therapy of cardiovascular and cerebrovascular diseases such as atherosclerosis, thrombi and cerebral post-stroke nerve function deficit. The formulaI is NH2-Leu-D-Leu-Ser-Gly-Val-R whitmantide A: R=D-Leu-Gly-COOHwhitmantide B: R=D-Leu-Gly-Gly-COOH whitmantide C: R=COOH.

Description

technical field [0001] The invention relates to the fields of traditional Chinese medicines, natural medicines and health products, in particular to a class of leech polypeptides with antithrombotic and cerebral nerve cell protection functions and applications thereof. Background technique [0002] According to the World Health Organization, cardiovascular and cerebrovascular diseases are the number one cause of death in the world. Atherosclerosis, stroke, myocardial infarction, and hemiplegia are common cardiovascular and cerebrovascular diseases. The clinical treatment drugs for cardiovascular disease have many adverse reactions such as drug resistance and high risk of hemorrhage, and there is currently a lack of effective drugs for neurological function repair after stroke. Polypeptide has good biocompatibility, strong specificity, low toxicity, is not easy to accumulate in the body, and has less interaction with other components, but has the defect of easy enzymatic ina...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/06A61K38/08A61P7/02A61P9/10
CPCA61K38/00A61P7/02A61P9/10C07K7/06
Inventor 叶文才王磊张紫月
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com